-
People aged 3-17 can use inactivated new coronavirus vaccine urgently
Time of Update: 2021-06-16
Cui Gang, the second-level inspector of the CDC of the National Health Commission , introduced at the press conference of the Joint Prevention and Control Mechanism of the State Council on the 11th that at present, China's new crown virus vaccination is mainly carried out for people over 18 years old, and the relevant state departments have approved 3- 17-year-olds can start emergency use of the new coronavirus inactivated vaccine .
-
"Night owl" violates the biological clock or is more prone to depression
Time of Update: 2021-06-16
Researchers from the University of Exeter in the United Kingdom extracted data from more than 450,000 British adults from the British Biomedical Library, and used Mendelian randomization to analyze whether these genes are causally related to seven psychological problems such as severe depression and feelings of happiness.
-
Health Commission: 21 newly diagnosed cases on the 9th, including 6 in the local area
Time of Update: 2021-06-16
As of 24:00 on June 9, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 416 confirmed cases (including 12 severe cases), a total of 86,285 cured and discharged cases, and a total of 4,636 deaths.
-
Qilu enters the market with annual sales of $1.9 billion blockbuster drugs and Chengdu Beite competes for the first imitation
Time of Update: 2021-06-16
Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval .
-
Notice of the Fifth Batch of National Clinical Medical Research Center Application Work
Time of Update: 2021-06-16
57 All relevant units: In accordance with the overall deployment of the "National Clinical Medical Research Center Five-Year (2017-2021) Development Plan" (Guoke Fashe [2017] No.
5. The construction review of the National Clinical Medical Research Center includes three procedures: formal review, material review, and comprehensive review .
-
China Disease Control: The best way to prevent new coronary pneumonia is to get vaccinated
Time of Update: 2021-06-16
Medium disease control: the best way to prevent new coronary pneumonia is still vaccination At a press conference held by the Joint Prevention and Control Mechanism of the State Council today (11th) , Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention's immunization program, said in response to questions about the effectiveness of vaccine protection that the best way to prevent new coronary pneumonia is to get vaccinated .
-
The 2021 medical insurance catalog adjustment starts!
Time of Update: 2021-06-16
The medicines in the medical insurance catalogue are the exclusive negotiated medicines whose agreement expires on December 31, 2021, and the payment standard needs to be re-determined in accordance with the agreement; from January 1, 2016 to June 30, 2021, approved by the National Food and Drug Administration , Indications or functional indications have undergone major changes, and the company takes the initiative to declare and adjust drugs that limit the scope of payment .
-
Mengdi Pharmaceuticals China business bidding hot!
Time of Update: 2021-06-16
The two are actually the same company, and Purdue Pharmaceutical's previous quagmire in the United States in the quagmire of high-priced compensation was the fuse for Mundi Pharmaceuticals to sell its Chinese business .
-
Chinese experts discover new genetic genes that cause heart teratogenesis
Time of Update: 2021-06-16
The reporter learned on the 9th that the joint study of the National Children's Medical Center (Shanghai), the Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University School of Medicine, Professor Fu Qihua's team, and Zhang Zhen's team has clarified the molecular mechanism of the occurrence of heart structural abnormalities caused by the loss of SORBS2 gene function .
-
New study finds cause of lung damage caused by new coronavirus
Time of Update: 2021-06-16
The model shows how these two proteins interact, helping to explain how the virus causes extensive lung damage in particularly vulnerable patients with new coronary pneumonia, and escapes the lungs to infect other organs .
-
Health Commission: 22 newly diagnosed cases on the 10th, including 9 from the local area
Time of Update: 2021-06-16
As of 24:00 on June 10, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 426 confirmed cases (including 12 severe cases), 86,297 cured and discharged cases, and 4,636 deaths.
-
Research on domestically produced original innovative drugs led by Chinese scholars brings new results
Time of Update: 2021-06-16
The subject of Xu Ruihua's report is "JUPITER-02: A randomized, double-blind, phase III clinical study comparing teriprizumab or placebo combined with gemcitabine and cisplatin in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma", He is also the chief scientist of this research .
-
Can people over 60 be vaccinated?
Time of Update: 2021-06-16
Can the standards be unified in various places, and will the Health and Health Commission issue specific guidance?State Council In this regard, Cui Gang, the second-level inspector of the CDC of the National Health Commission, said that in accordance with the overall arrangement and deployment of new crown vaccination, relevant departments have made corresponding detailed arrangements for the vaccination of various groups of people.
-
Nuocheng Jianhua's FGFR inhibitor gunagratinib was approved as an orphan drug by the U.S. FDA
Time of Update: 2021-06-16
Nuocheng Jianhua announced today that the company's self-developed highly selective pan-FGFR (fibroblast growth factor receptor) inhibitor gunagratinib (ICP-192) has been granted Orphan Drug designation by the U.
Among the 12 FGF/FGFR gene mutation-positive patients who completed at least one tumor evaluation, the objective response rate (ORR) was 33.
-
Baiyang Pharmaceutical's IPO plans to publicly issue 52.6 million shares, preliminary inquiry on June 15
Time of Update: 2021-06-16
On June 9th, Baiyang Pharmaceutical issued an initial public offering and listed on the Growth Enterprise Market (GEM) preliminary inquiry and promotion announcement.
(Sina Pharmaceutical News ) On June 9th, Baiyang Pharmaceutical issued an initial public offering and listed on the Growth Enterprise Market (GEM) preliminary inquiry and promotion announcement.
-
VVS Medical completed nearly 100 million yuan in A+ round of financing
Time of Update: 2021-06-16
(Arterial Network) It was learned on June 9 that Suzhou VVS Medical Technology Co.
Prior to this, VVS Medical announced in April 2021 that it had completed a round of financing of nearly 100 million yuan .
-
Longyu Pharmaceutical Cavosonstat in the treatment of moderate to severe asthma in China and the U.S. Phase II clinical trial launched
Time of Update: 2021-06-16
(hereinafter referred to as "Langyu Pharmaceutical") announced the official launch of Phase II clinical trials of Cavosonstat (N91115), a new class I drug developed by it for the treatment of moderate to severe asthma .
-
Health Commission: 16 newly diagnosed cases on the 8th, including 8 local cases
Time of Update: 2021-06-16
The National Health Commission notified on the 9th that from 0-24 o'clock on June 8th, 31 provinces (autonomous regions, municipalities) and the Xinjiang Production and Construction Corps reported 16 new confirmed cases, including imported cases.
-
Health Commission: 33 new confirmed cases and 19 local cases
Time of Update: 2021-06-16
As of 24:00 on June 7, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 409 confirmed cases (including 10 severe cases), 86,255 cured and discharged cases, and 4,636 deaths.
-
Yang Fan, vice president of Blue Sail Medical, applied for resignation due to personal reasons
Time of Update: 2021-06-16
On June 8, Blue Sail Medical issued an announcement on the Shenzhen Stock Exchange stating that the company’s vice president, Mr.
( Sina Pharmaceutical News )On June 8, Blue Sail Medical issued an announcement on the Shenzhen Stock Exchange stating that the company’s vice president, Mr.
